Retrospective observational study of the use of artemether-lumefantrine in the treatment of malaria in Japan
| Autor: | Chihiro Hasegawa, Haruhiko Maruyama, Yasutaka Mizuno, Fukumi Nakamura-Uchiyama, Yukihiro Yoshimura, Tetsuo Hasegawa, Satoshi Kutsuna, Mikio Kimura, Michiko Koga, Yuichi Katanami, Yasuyuki Kato, Tadashi Kikuchi, Saho Takaya, Taiichiro Kobayashi |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Hemolytic anemia Adult Male Pediatrics medicine.medical_specialty Anemia Hemolytic Artemether/lumefantrine medicine.medical_treatment 030231 tropical medicine 030106 microbiology Treatment failure 03 medical and health sciences Antimalarials Young Adult 0302 clinical medicine Japan parasitic diseases medicine Humans Treatment Failure Malaria Falciparum Adverse effect Aged Retrospective Studies Chemotherapy biology business.industry Artemether Lumefantrine Drug Combination Public Health Environmental and Occupational Health Retrospective cohort study Plasmodium falciparum Middle Aged medicine.disease biology.organism_classification Infectious Diseases Treatment Outcome Female Safety business Malaria medicine.drug |
| Zdroj: | Travel medicine and infectious disease. 22 |
| ISSN: | 1873-0442 |
| Popis: | Background The Research Group on Chemotherapy of Tropical Diseases, Japan, introduced artemether–lumefantrine (AL) in late 2002, mainly for treating uncomplicated Plasmodium falciparum malaria. Because AL was on the market in Japan in March 2017, the effectiveness and safety of AL were analyzed to help medical personnel use AL optimally. Methods Case report forms submitted by the attending physicians were analyzed. When necessary, direct contact with the attending physicians was made to obtain detailed information. Results Effectiveness analysis was performed for 62 cases and safety analysis was performed for 66 cases. In P. falciparum malaria, the overall cure rate was 91.1% (51/56), of which the cure rates for Japanese and non-Japanese patients were 82.1% (23/28) and 100% (28/28), respectively. The successfully treated cases included severe P. falciparum malaria, with parasite densities exceeding 500,000/μL. Adverse events were reported in 14 patients, including delayed hemolytic anemia which occurred in the top four highest parasitemic cases. Conclusions AL treatment failure in P. falciparum malaria may not be rare among non-immune individuals, including Japanese. The possibility of delayed hemolytic anemia, which occurs preferentially in high parasitemic cases, should be considered following AL treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect